Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Neurovance Inc.

Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2012
Status: Acquired

BioCentury | Jul 13, 2018
Company News

Otsuka acquiring antibody play Visterra

BioCentury | Jul 11, 2018
Company News

Otsuka acquiring antibody play Visterra

BioCentury | Apr 20, 2018
Finance

Refilling Alexion’s cupboard

Why Wilson takeout is a smart but small step towards filling Alexion’s pipeline
BioCentury | May 23, 2017
Company News

Alexion shuffles management again

BioCentury | Mar 7, 2017
Company News

Neurovance, Otsuka deal

BioCentury | Mar 3, 2017
Company News

Otsuka acquiring ADHD company Neurovance

BioCentury | Dec 15, 2016
Company News

Management tracks

BioCentury | Aug 1, 2016
Clinical News

Centanafadine SR: Phase IIb data

BioCentury | Jan 18, 2016
Clinical News

Centanafadine SR: Phase IIb started

BioCentury | Feb 2, 2015
Emerging Company Profile

Three's company

How the serotonin component of Neurovance's ADHD candidate could set it apart
Items per page:
1 - 10 of 21